An independent peptide reference — no sellers, every claim sourced

Ventfort

Also known as Ventfort Cytomax, vessel peptide complex capsule, vascular peptide bioregulator

Calf blood-vessel extract capsule from the Khavinson Cytomax line, with no published study by that name.

preclinical Immune & longevity supplement

At a glance

Category
Immune & longevity
Status
supplement
Made from
animal-derived Sold as a peptide complex extracted from the vascular wall of young cattle. A review from the originating institute describes a polypeptide complex extracted from calf vessel wall, though it is published under a different trade name and is not about this capsule 4. PeptideX has not been able to verify the species, country of origin or age of the source animals for Ventfort itself; no such information reaches the buyer.
Route
oral capsule
Half-life
Not measured. No pharmacokinetic study of this product exists in humans or animals.
Molecular weight
No single value applies. This is a tissue extract rather than a defined molecule - a mixture of free amino acids and short peptides whose composition is neither disclosed nor standardised in any publicly available specification.

Ventfort is a capsule product in the 'Cytomax' range of the Khavinson peptide bioregulator programme - the natural organ-extract half of that programme, as opposed to the 'Cytogen' range of chemically synthesised short peptides, of which the vascular member is the tripeptide Vesugen. It is sold internationally through online retailers as a food supplement. It is not an approved medicine anywhere in the EU or the US and no regulator has assessed a dossier for it. The Cytomax capsules are widely stated to be registered in Russia as BAD (biologically active food supplements), a notification regime that carries no efficacy assessment; PeptideX could not open the Russian register from outside Russia to confirm that Ventfort specifically appears in it, so this is recorded as an unverified claim. Even confirmed, it would describe a notification rather than an approval.

Doping status: Not listed by name on the WADA Prohibited List

Checked against the WADA 2026 Prohibited List. For a specific product and country, Global DRO is the lookup athletes are expected to use — the List names substances, not brand names.

This is bovine tissue swallowed as a capsule, and the sourcing question that follows deserves stating plainly rather than either dismissing or dramatising. The WHO tables on tissue infectivity in transmissible spongiform encephalopathies place blood vessels in Table IB, the lower-infectivity category, rather than in the high-infectivity category that covers central nervous tissue, and the same document notes that the oral route is a comparatively inefficient route of transmission 5. That is a genuinely less alarming starting point than for a brain or pineal extract. What remains unanswered is the same for all of these products: a medicine made from bovine material must document the BSE risk status of the country of origin, the age of the animals, the tissue category and batch traceability 6, and a food supplement bought online documents none of that to the buyer. No case of TSE transmission has been attributed to these capsules; that is not the same as having checked. And for a reader who is vegetarian or vegan, or who keeps halal or kosher, the relevant fact needs no risk assessment at all: this is animal tissue.

This is a short entry. There is little or no published research on this compound, so there is correspondingly little to report. Empty dosing or reconstitution sections mean no credible figures exist — not that they were left out.

Mechanism of action

Ventfort belongs to the doctrine of 'peptide bioregulators' from Khavinson's group at the St Petersburg Institute of Bioregulation and Gerontology, which holds that short peptides extracted from an organ selectively restore the function of that same organ by entering cell nuclei and directing gene expression 3. Here, an extract of vessel wall is said to restore vascular wall function, normalise lipid handling and slow vascular ageing. The premise of tissue specificity is the least substantiated assumption in the whole programme: there is no accepted mechanism by which fragments of a few residues, chemically indistinguishable from ordinary proteolytic breakdown material found throughout the body, would navigate selectively to the endothelium and bind sequence-specifically to promoter DNA.

The oral route adds a second unanswered question. Short peptides presented to the gut are substrates for intestinal and pancreatic peptidases, and there is no published absorption or bioavailability study for this product. A review from the originating institute reports a range of vascular and haemostatic effects for a calf-vessel polypeptide complex in animal models, but that work concerns an injectable preparation marketed under another name 4 and cannot be read as a mechanism for a capsule.

What the research shows

There is no evidence for Ventfort. A PubMed search for the name returns no records and ClinicalTrials.gov returns no registered study, as of July 2026 12. Claims made for it on retail pages are borrowed either from the synthetic tripeptide Vesugen or from animal work on an injected calf-vessel preparation published under a different name 4. Those are different products; treating their literature as this capsule's evidence is the mistake worth naming explicitly.

Research in humans

No published human study of Ventfort. No trial, no case series, no pharmacokinetic or tolerability data. The literature on this product by name is empty 12.

Animal and lab research

No published animal study of Ventfort by name. Animal work on a calf-vessel polypeptide complex from the originating institute exists, reporting effects on atherosclerosis, lipid metabolism, haemostasis and vessel wall repair in animal models, but it is a review from the group that developed the preparation, it concerns a differently named injectable product, and it is not evidence about this capsule 4.

Caveats. There is nothing to appraise for the product itself. Beyond that: the product is an undefined tissue extract with no standardised or disclosed composition, so batches are not guaranteed to be the same substance; the published work in this programme used injection while this is swallowed; and the animal work that does exist for a vessel complex comes from the originating group without independent replication 4.

What it is used for

  • Sold and self-administered in capsule courses as a general vascular or circulatory support supplement, without a validated indication and without a single published study of the product 12
  • Presented by sellers as the natural counterpart of the synthetic tripeptide Vesugen; the evidence offered for that framing was generated with Vesugen or with an injected vessel preparation, not with this capsule 4

Dosing

  • No dose is given here, because none has been studied. There is no published human study of this product, no dose-finding work, no maximum tolerated dose, no pharmacokinetics and no dose-response curve 12.
  • Capsule course schedules circulate on retail pages. They are packaging conventions rather than findings; the protocol section below records the common one explicitly as a vendor convention with no published basis, not as a validated dose.
  • A dose taken from Vesugen or from an injected vessel preparation is not a dose for this capsule. A milligram figure on a capsule of undefined extract is a mass of powder, not a quantity of active substance.

These figures describe what the literature and published protocols report. They are not advice and not a dosing instruction.

Protocols

Vendor capsule course (packaging convention, no published basis)

user protocol — not validated

Source: Retailer instructions and Khavinson-programme course conventions

This is not a validated schedule. It is a pattern that circulates among users and sellers, reproduced because it is what people actually follow — not because it has been tested. No trial established these doses, this interval or this duration, and nobody is checking what is in the vial. Treat every number below as an assertion, not a finding.

A courseone to two capsules a day for 10 to 30 days, the length set by the pack size
Repeattypically two or three courses a year, with sellers suggesting more frequent repeats from around age 40

This is a packaging convention, not a dose. The 10- to 30-day length is set by the number of capsules in the pack, and the 'two or three courses a year' cadence comes from the sellers' own promotional guidance rather than from any study of this product 12. Because the capsule contains an undefined tissue extract, a figure given in capsules or milligrams describes a mass of powder rather than a quantity of any identified active substance, and no published human study establishes that any of it is absorbed or does anything.

Schedules are reproduced as their source states them. Units, IU and milligrams explains why the figures are not interchangeable between products.

Reconstitution

Supplied as capsules taken by mouth. Nothing is reconstituted and no injection is involved.

Safety

Side effects

  • Unknown. No systematic safety monitoring of this product has been published 12; an absence of reported adverse effects reflects the absence of any study rather than evidence of safety
  • Allergic reaction to foreign animal protein is the predictable class risk for any animal tissue extract, though the oral route makes systemic sensitisation less likely than injection would
  • No toxicology, carcinogenicity or reproductive toxicity programme for this product exists in the internationally accessible literature
  • The identity and purity of the contents of a capsule bought online cannot be verified by the buyer, and no independent analysis has been published

Do not use if

  • Pregnancy and breastfeeding - no data of any kind
  • Children and adolescents - no data
  • Known hypersensitivity to bovine protein
  • Anyone avoiding animal-derived material on dietary or religious grounds - this is animal tissue 5
  • Anticoagulant or antiplatelet treatment, and any bleeding disorder - effects on haemostasis have been claimed for vessel preparations in this programme in animal models 4 and have never been characterised for this capsule in a human being; the interaction is unstudied rather than excluded
  • Active, past or suspected malignancy - the claimed mechanisms are transcriptional and proliferative and have never been examined for oncological consequences in this product

Interactions

Not studied. No interaction study of any kind exists for this product 12. The one theoretical relationship worth naming is with anticoagulants and antiplatelet agents, because effects on coagulation, platelet function and fibrinolysis have been claimed for a vessel polypeptide complex in animal models from the originating group 4. That is a reason to be cautious about an untested interaction, not a demonstration that one exists.

Sources